Oxy210 as an anti-fibrotic and immune-modulating approach for cystic fibrosis
Official title: Examination of anti-fibrotic and immune modulatory effects of Oxy210 for targeting cystic fibrosis
Funded at Max Biopharma, INC. · NIH-11403555 · Data updated 2026-11-12
A small-fund, early-phase program tests whether Oxy210 can reduce lung scarring and abnormal immune responses in people with cystic fibrosis.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Max Biopharma, INC. NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 7, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $364,853 |
| NIH project number | 1R43HL184363-01A1 |
| Project ID | NIH-11403555 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with cystic fibrosis, particularly those with inflammatory and fibrotic lung involvement, could be eligible for future translational or trial opportunities.
✕Less likely to help
Not all pwCF may benefit, especially if fibrosis is not a dominant driver of their disease or if there are safety concerns with the therapy.
What this research studies
This grant explores whether Oxy210 can lessen fibrotic changes and dampen harmful immune activity in the lungs of people affected by cystic fibrosis. The work uses cellular and possibly animal models to examine anti-fibrotic and immune-modulating effects, with a focus on pathways involving AP-1 and related inflammatory processes. If successful, findings could inform future trials aiming to complement CFTR-targeted therapies and improve lung function and quality of life for pwCF. The project is designed to generate preliminary data on safety and biological activity to guide further development in CF care.
Why it matters
Potential benefit: If successful, this work could lead to new treatment options that reduce lung fibrosis and inflammation in cystic fibrosis, potentially slowing disease progression.
How similar studies have gone: Preliminary data from related anti-fibrotic and immune-modulating strategies in CF or similar lung diseases have shown potential benefits in reducing inflammation and fibrosis in early studies.
Where this research is happening
-
Max Biopharma, INC.
Los Angeles, United States Active
Researchers
- Principal investigator: Parhami, Farhad — Max Biopharma, INC.
- Study coordinator: Parhami, Farhad
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.